Results 61 to 70 of about 125,674 (260)

Regulation of hTERT by BCR-ABL at multiple levels in K562 cells

BMC Cancer, 2011
Background The cytogenetic characteristic of Chronic Myeloid Leukemia (CML) is the formation of the Philadelphia chromosome gene product, BCR-ABL. Given that BCR-ABL is the specific target of Gleevec in CML treatment, we investigated the regulation of ...
Chai Juin Hsien, Zhang Yong, Tan Wei Han, Chng Wee Joo, Li Baojie, Wang Xueying   +5 more
doaj   +1 more source

Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL. [PDF]

PLoS ONE, 2015
Notch signalling is critical for haemopoietic stem cell (HSC) self-renewal and survival. The role of Notch signalling has been reported recently in chronic myeloid leukaemia (CML) - a stem cell disease characterized by BCR-ABL tyrosine kinase activation.
Abdullah Aljedai, Anne-Marie Buckle, Prashant Hiwarkar, Farhatullah Syed   +3 more
doaj   +1 more source

Activation of tyrosine kinases by mutation of the gatekeeper threonine. [PDF]

, 2008
Protein kinases targeted by small-molecule inhibitors develop resistance through mutation of the gatekeeper threonine residue of the active site. Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth ...
Azam, Mohammad, Daley, George, Gray, Nathanael, KURIYAN, John, Seeliger, Markus   +4 more
core   +1 more source

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

Cancer Research, 2005
Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients with chronic myelogenous leukemia (CML). Despite durable responses in most chronic phase patients, relapses have been observed and are much more prevalent in ...
T. O'hare, D. Walters, Eric P. Stoffregen, Taiping Jia, P. Manley, J. Mestan, S. Cowan-Jacob, F. Lee, M. Heinrich, M. Deininger, B. Druker   +10 more
semanticscholar   +1 more source

Stafib‐2‐CR: an Improved Nanomolar and Selective Inhibitor of the Transcription Factor STAT5b Developed by Conformational Restriction of Stafib‐2

Chemistry – A European Journal, EarlyView.
Conformational restriction strategies to increase the activity and selectivity of the STAT5b inhibitor Stafib‐2 are presented. The best conformationally restricted inhibitor Stafib‐2‐CR has threefold higher activity against STAT5b than Stafib‐2. A cell‐permeable prodrug of Stafib‐2‐CR inhibits phosphorylation of STAT5b in cultured human leukemia cells ...
Theresa Münzel, Angela Berg, Christoph Protzel, Sylvie Schäfer, Alexander Jensen‐Feinhals, Thorsten Berg   +5 more
wiley   +1 more source

Inhibition of BCR/ABL protein expression by miR-203 sensitizes for imatinib mesylate. [PDF]

PLoS ONE, 2013
Selective inhibition of BCR/ABL expression by RNA interference has been demonstrated as an effective strategy in CML treatment and a reversal to imatinib resistance.
Yajuan Li, Ying Yuan, Kun Tao, Xin Wang, Qing Xiao, Zhenglan Huang, Liang Zhong, Weixi Cao, Jianping Wen, Wenli Feng   +9 more
doaj   +1 more source

Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. [PDF]

, 1995
To determine the functional importance of Ras in transformation by Abl oncogenes, we used a genetic approach to measure the effect of impaired Ras activity on the ability of Bcr-Abl or v-Abl to transform cells.
McLaughlin, J, Sawyers, CL, Witte, ON
core  

CREB is a critical regulator of normal hematopoiesis and leukemogenesis [PDF]

, 2008
The cAMP-responsive element binding protein (CREB) is a 43-kDa nuclear transcription factor that regulates cell growth, memory, and glucose homeostasis. We showed previously that CREB is amplified in myeloid leukemia blasts and expressed at higher levels
Akashi, Akashi, Bai, Bottazzi, Bruserud, Cheng, Christensen, Conkright, Crans-Vargas, Deepa B. Shankar, Dejah R. Judelson, Desdouets, Deshpande, Elliot M. Landaw, Fried, Fu, Hestdal, Impey, Ingrid Schmid, Jamieson, Jenny Chang, Jerry C. Cheng, Kathleen M. Sakamoto, Kentaro Kinjo, Kim, Kinjo, Kohn, Kondo, Koschmieder, Koya, Krishan, Kwon, Lee, Mayr, Mendoza, Miyoshi, Montminy, Ninomiya, Noriyuki Kasahara, Passegué, Ravi Bhatia, Rehemtulla, Renata Stripecke, Scherr, Shah, Shankar, Shankar, Shaywitz, Stripecke, Traver, Tuschl, Van Etten, Ventura, Winston S. Wu, Wong, Yuan   +55 more
core   +3 more sources

Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?

ESC Heart Failure, Volume 12, Issue 2, Page 1447-1454, April 2025.
This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo, Daniela Di Lisi, Antonio Cannatà, Federica Manfrè, Celeste Vullo, Marco Santoro, Ciro Botta, Salvatrice Mancuso, Sergio Siragusa, Alfredo Ruggero Galassi, Giuseppina Novo   +10 more
wiley   +1 more source

Artificial intelligence strategies for predicting kinase inhibitor resistance: A comprehensive review of methods, challenges, and future perspectives

Journal of Intelligent Medicine, EarlyView.
Abstract Kinase inhibitors are essential in targeted cancer therapy, yet resistance often emerges through secondary mutations, activation of compensatory signaling pathways, or drug‐efflux mechanisms. Artificial intelligence (AI) provides a workflow‐based strategy rather than a list of unrelated tools for predicting and addressing kinase‐inhibitor ...
Faris Hassan, Mohanad Ali Deifallah, Alaa Zaghloul, Rania Elgohary   +3 more
wiley   +1 more source